How AstraZeneca created an automated DNA assembly framework to support rapid and cost-efficient construct generation
It takes around 10 years and millions to sometimes billions of dollars for most new drugs to
make it to market. Unsurprisingly, this timeline and cost profile doesn’t cut it for drug development patients, companies, and clinical trial sponsors. One of the earliest steps that can be optimized is DNA construct development for early drug discovery, as it affects all downstream processes.
To address this, AstraZeneca developed a comprehensive DNA assembly framework, which
they integrated into Benchling to support rapid, cost-efficient, and scalable construct generation. Their unique solution takes an unheard-of 3 weeks and led to cost savings from 50 to 90%.
Read this case study to learn biopharma is adopting technology to reach critical R&D
milestones faster.
Fill out the form to download